Core Viewpoint - The board of directors of Mayinglong Pharmaceutical Group Co., Ltd. approved the 2025 semi-annual report and the remuneration plans for directors and senior management during the 21st meeting of the 11th board session held on August 27, 2025 [1][2]. Group 1: 2025 Semi-Annual Report - The 2025 semi-annual report was approved with unanimous support from the board members, indicating a strong consensus on the report's content [1]. Group 2: Remuneration Plans - The independent directors will receive a fixed annual allowance of 180,000 yuan (including tax), paid monthly [2]. - Non-independent directors not involved in daily management will receive a fixed annual allowance of 120,000 yuan (including tax), also paid monthly [2]. - The remuneration for non-independent directors and senior management involved in daily operations will consist of a basic salary and performance-based pay, determined by their roles and the company's annual performance assessment [2].

"垆边人似月，皓腕凝霜雪。" 难怪大家都说 肤白是美貌的加持器 ，这女子面如玉、肤如雪的，连 皎洁的月光也瞬间黯然失色~ 洞见（DJ00123987）——不一样的观点，不一样的故事，3000万人订阅的微信大号。点击标题下蓝字"洞见"关 注，我们将为您提供有价值、有意思的延伸阅读。 而且一白遮三丑，假如面容白到发亮，斑点等小瑕疵也都瞬间隐形。 素颜宛若出水芙蓉般，一颦一笑都牵动人心。 我想没有女生是不想拥有干净无瑕的皮肤的~ 只是 随着年岁增长、工作压力、熬夜、防晒不到位... 脸上开始 浮现许多斑斑点点 ，且皮肤还变得 又黑 又黄 。 俗话说 一黑显百丑 ，皮肤一黑，各种瑕疵都被无限放大。 斑点 、皱纹 、黑眼圈... 人瞬间老了10岁。 也不是没想过自救的，只是—— ❌ 护肤品见效慢，难以看出效果； ❌成分太猛的，又怕刺激皮肤烂脸； ❌做医美皮秒爆破打斑也容易反黑，且一次千元起... 普通人如何花小钱养出一张干净的脸呢？ 今天，就来给大家推荐一款手持 「祛斑美白类」 特证 、能阻黑、 让你肌肤恢复初白本色 的美白好物。↓ 『马应龙八宝焕白淡斑精华霜』 马应龙 这牌子，大家应该都不陌生了吧~ 看似凭痔疮膏火遍 ...

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.32% on August 29, with Darentang leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Performers - Darentang (600329) closed at 46.11, with a rise of 4.80% and a trading volume of 167,100 shares, amounting to a transaction value of 765 million [1] - Enwei Pharmaceutical (301331) increased by 2.22% to close at 35.94, with a trading volume of 15,900 shares [1] - Jianmin Group (600976) rose by 2.19% to 42.43, with a transaction value of 208 million [1] Underperformers - Qidi Pharmaceutical (000590) decreased by 3.11% to 11.84, with a trading volume of 129,400 shares and a transaction value of 155 million [2] - Tianmu Pharmaceutical (600671) fell by 2.89% to 19.81, with a transaction value of 209 million [2] - Buchang Pharmaceutical (603858) saw a decline of 2.55% to 19.51, with a trading volume of 198,400 shares [2] Capital Flow - The traditional medicine sector experienced a net outflow of 510 million from institutional investors, while retail investors saw a net inflow of 469 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Darentang had a net inflow of 77.24 million from institutional investors, but a net outflow of 59.46 million from retail investors [3] - Yunnan Baiyao (000538) saw a net inflow of 55.91 million from institutional investors, while retail investors had a net outflow of 0.83 million [3] - Zhendong Pharmaceutical (300158) experienced a net inflow of 48.61 million from institutional investors, but a significant net outflow of 79.17 million from retail investors [3]

Core Viewpoint - The company has demonstrated resilient growth in a challenging macroeconomic environment, achieving revenue of 1.949 billion yuan and a net profit of 343 million yuan in the first half of 2025, reflecting year-on-year increases of 1.11% and 10.04% respectively [1][3]. Group 1: Financial Performance - In the first half of 2025, the company reported revenue of 1.949 billion yuan, a year-on-year increase of 1.11% [1][3]. - The net profit attributable to shareholders reached 343 million yuan, marking a 10.04% increase compared to the previous year [1][3]. - The company's net profit excluding non-recurring items was 322 million yuan, which is a 4.24% increase year-on-year [1][3]. Group 2: Business Strategy and Market Position - The company is enhancing its pharmaceutical operating capabilities by optimizing its distributor structure and expanding product offerings, resulting in a 4.51% increase in revenue from the parent company [2]. - The company is actively cultivating new growth drivers in ophthalmology and dermatology, with significant progress in product registration and market expansion [3]. - The company is leveraging its strengths in the anorectal market to extend into health-related products, including the launch of new hygiene products [2]. Group 3: Operational Adjustments - The company is adapting to policy changes in the healthcare sector, focusing on optimizing its medical project structure and expanding non-insured business revenues [4]. - The company is restructuring its retail pharmacy operations to enhance health promotion functions and exploring online business opportunities [4]. - The company is increasing brand marketing efforts through various promotional activities and partnerships to enhance market presence [5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown strong growth in its hemorrhoid treatment products and is expanding into the wet wipes business, which is expected to drive future growth [6][7] - The company's revenue for H1 2025 reached 1.949 billion yuan, a year-on-year increase of 1.11%, while the net profit attributable to shareholders was 343 million yuan, up 10.04% year-on-year [5][6] Summary by Sections Recent Performance - In the last year, the company's stock performance has been relatively weak compared to the market, with a 12-month return of 5.1% compared to the Shanghai and Shenzhen 300 index's 35.8% [4] Financial Highlights - For H1 2025, the company reported operating income of 1.949 billion yuan and a net profit of 343 million yuan, with a significant increase in operating cash flow by 37.94% to 311 million yuan [5][6] - The second quarter saw a net profit of 140 million yuan, reflecting a year-on-year growth of 22.24% [6] Product Performance - The hemorrhoid treatment products experienced a 7% year-on-year growth despite a high base, while the hospital market showed slight declines due to policy impacts [6] - The wet wipes segment has rapidly expanded, leveraging the company's established brand recognition in the anorectal health sector [7] Future Projections - Revenue forecasts for 2025-2027 are adjusted to 4.239 billion yuan, 4.835 billion yuan, and 5.556 billion yuan respectively, with net profit projections of 624 million yuan, 729 million yuan, and 867 million yuan [7][9] - The company is expected to maintain a strong position in the hemorrhoid treatment market and benefit from the growth of its wet wipes business [7]

格隆汇8月28日丨马应龙(600993.SH)发布2025年半年度报告，报告期实现营业收入19.49亿元，同比增长1.11%；归属上市公司股东的净利润3.43亿元，同比增长10.04%；扣除非经常性损 ...

第十一届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600993 证券简称：马应龙 公告编号：临 2025-020 马应龙药业集团股份有限公司 马应龙药业集团股份有限公司（以下简称"公司"）第十一届董事会第二 十一次会议于 2025 年 8 月 27 日以通讯方式召开，本次会议通知及会议材料于 2025 年 8 月 18 日以电话及电子邮件形式发出。公司九名董事均在规定时间内对 本次会议议案进行了表决，本次会议的召集、召开符合《公司法》、《公司章 程》等有关规定，会议审议通过了以下议案： 一、《2025 年半年度报告》 同意：9 票，反对：0 票，弃权：0 票 董事会审议前，该议案已经第十一届董事会审计委员会审议通过。 （一）《关于独立董事津贴方案的议案》 同意：6 票，反对：0 票，弃权：0 票 独立董事毛鹏、齐珺、梅之南回避表决。 公司独立董事采取固定津贴形式领取报酬，津贴标准为每人每年18万元（含 税），按月发放。 （二）《关于其他董事及高级管理人员薪酬（津贴）方案的议案》 1 ...

马应龙药业集团股份有限公司2025 年半年度报告 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2025 年半年度报告 1 / 176 马应龙药业集团股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人陈平、总经理夏有章、主管会计工作负责人茅涛及会计机构负责人（会计主管 人员）彭玲声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的公司发展战略、经营计划等前瞻性描述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 ...

马应龙公告，2025年上半年营业收入19.49亿元，同比增长1.11%。净利润3.43亿元，同比增长10.04%。 ...

Group 1 - The company announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., received the drug registration certificate for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration [1][2] - The drug is indicated for the treatment of allergic conjunctivitis-related eye itching and was first approved in the United States in 2004, with the original import approval in China granted in 2020 [2] - The domestic market sales of Olopatadine Hydrochloride Eye Drops reached 255 million yuan in 2023, and the company's cumulative R&D investment for this drug is 4.9224 million yuan [2] Group 2 - The approval of the drug registration certificate will help enrich the company's ophthalmic product line [3] - The production and sales of the drug are subject to uncertainties due to industry policies and market competition [3]